Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-006 first-line lenvatinib plus pembrolizumab and platinum-pemetrexed in metastatic nonsquamous NSCLC
MOH_2019-02-26_004927Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lenvatinib, pembrolizumab, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoints: Safety of lenvatinib in combination, Disease control / progression delay and 1 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2019-02-26_004927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-26_004927.